Stockreport

The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients

MEDICINES  (MDCO) 
Last medicines earnings: 10/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: themedicinescompany.com/investors
PDF ­ ORION-9 study met all primary and secondary efficacy endpoints­ Inclisiran demonstrated durable and potent efficacy and excellent safety in a patient population where [Read more]